Literature DB >> 28366512

The role of surgery in anaplastic thyroid cancer: A systematic review.

Shirley Hu1, Samuel N Helman2, Elyse Hanly3, Ilya Likhterov4.   

Abstract

OBJECTIVE: To elucidate the role of surgery in the management of anaplastic thyroid cancer.
METHODS: Ovid MEDLINE, Cochrane Library, and Google Scholar databases were searched for publications from December 2000 to July 2016. Selection criterion was a focus on the management of anaplastic thyroid cancer in adults. Studies addressing only nonsurgical management and review articles were excluded. Data extraction was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Kaplan-Meier analysis was performed on a subset of patients.
RESULTS: 40 publications were included in the study. Approaches to unresectability and interpretations of resection varied widely. For patients undergoing primary surgery, the median survival was 6.6months. The median survival for non-surgical patients was 2.1months. In the subgroup analysis, the median survival time for patients undergoing surgery was significantly longer in Stage IVB (p=0.022) but not IVC disease. Negative margins did not afford a statistically significant survival benefit.
CONCLUSION: Surgery is a mainstay of treatment for Stage IVA and IVB disease. For Stage IVC cancer, distant metastasis was not a strict criterion against surgical candidacy among surgeons. The extent of resection and the definition of resectability remain controversial. Negative margins did not significantly increase survival.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anaplastic thyroid cancer; Multimodality; Surgery; Surgical management; Thyroid cancer; Thyroidectomy

Mesh:

Year:  2017        PMID: 28366512     DOI: 10.1016/j.amjoto.2017.02.005

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  6 in total

Review 1.  Peptide Receptor Radionuclide Therapy in Thyroid Cancer.

Authors:  Sriram Gubbi; Christian A Koch; Joanna Klubo-Gwiezdzinska
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-30       Impact factor: 6.055

Review 2.  Anaplastic Thyroid Carcinoma: An Update.

Authors:  Arnaud Jannin; Alexandre Escande; Abir Al Ghuzlan; Pierre Blanchard; Dana Hartl; Benjamin Chevalier; Frédéric Deschamps; Livia Lamartina; Ludovic Lacroix; Corinne Dupuy; Eric Baudin; Christine Do Cao; Julien Hadoux
Journal:  Cancers (Basel)       Date:  2022-02-19       Impact factor: 6.639

3.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

4.  Identification of Hub Genes in Anaplastic Thyroid Carcinoma: Evidence From Bioinformatics Analysis.

Authors:  Liqi Li; Mingjie Zhu; Hu Huang; Junqiang Wu; Dong Meng
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

5.  Long-term survival of patients with anaplastic thyroid cancer after multimodal treatment.

Authors:  Haejun Lee; Soo Young Kim; Seok-Mo Kim; Ho-Jin Chang; Yong Sang Lee; Cheong Soo Park; Hang-Seok Chang
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

Review 6.  Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer.

Authors:  Prachi Mishra; Dipranjan Laha; Robert Grant; Naris Nilubol
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.